Abstract
The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | e270-e272 |
| Journal | American journal of therapeutics |
| Volume | 25 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1 2018 |
Fingerprint
Cite this
Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura. / Beckman, Joan D.; Rollins-Raval, Marian A.; Raval, Jay S.; Park, Yara A.; Mazepa, Marshall; Ma, Alice.
In: American journal of therapeutics, Vol. 25, No. 2, 01.03.2018, p. e270-e272.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura
AU - Beckman, Joan D.
AU - Rollins-Raval, Marian A.
AU - Raval, Jay S.
AU - Park, Yara A.
AU - Mazepa, Marshall
AU - Ma, Alice
PY - 2018/3/1
Y1 - 2018/3/1
N2 - The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.
AB - The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.
UR - http://www.scopus.com/inward/record.url?scp=85053903627&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053903627&partnerID=8YFLogxK
U2 - 10.1097/MJT.0000000000000517
DO - 10.1097/MJT.0000000000000517
M3 - Article
VL - 25
SP - e270-e272
JO - American Journal of Therapeutics
JF - American Journal of Therapeutics
SN - 1075-2765
IS - 2
ER -